RU2005136383A - Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов - Google Patents
Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов Download PDFInfo
- Publication number
- RU2005136383A RU2005136383A RU2005136383/14A RU2005136383A RU2005136383A RU 2005136383 A RU2005136383 A RU 2005136383A RU 2005136383/14 A RU2005136383/14 A RU 2005136383/14A RU 2005136383 A RU2005136383 A RU 2005136383A RU 2005136383 A RU2005136383 A RU 2005136383A
- Authority
- RU
- Russia
- Prior art keywords
- thrombin
- active ingredient
- agent
- increased
- pharmaceutical composition
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims 11
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims 4
- 229960002768 dipyridamole Drugs 0.000 title claims 4
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 title claims 4
- 229950010718 mopidamol Drugs 0.000 title claims 4
- 230000009424 thromboembolic effect Effects 0.000 title claims 4
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000002829 reductive effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 108090000190 Thrombin Proteins 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 229960004072 thrombin Drugs 0.000 claims 15
- 102000003790 Thrombin receptors Human genes 0.000 claims 13
- 108090000166 Thrombin receptors Proteins 0.000 claims 13
- 239000004480 active ingredient Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003524 antilipemic agent Substances 0.000 claims 5
- 239000005541 ACE inhibitor Substances 0.000 claims 4
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 206010047249 Venous thrombosis Diseases 0.000 claims 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 239000003472 antidiabetic agent Substances 0.000 claims 4
- 229940125708 antidiabetic agent Drugs 0.000 claims 4
- 230000003143 atherosclerotic effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 206010003178 Arterial thrombosis Diseases 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229960004676 antithrombotic agent Drugs 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000003073 embolic effect Effects 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229960001929 meloxicam Drugs 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 229940019331 other antithrombotic agent in atc Drugs 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Chemical group 0.000 claims 2
- 229960000371 rofecoxib Drugs 0.000 claims 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000007214 atherothrombosis Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical group N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
- 229960000288 dabigatran etexilate Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
- 229960005080 warfarin Drugs 0.000 claims 1
- 229960001522 ximelagatran Drugs 0.000 claims 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46516803P | 2003-04-24 | 2003-04-24 | |
| US60/465,168 | 2003-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005136383A true RU2005136383A (ru) | 2007-06-10 |
Family
ID=33311001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005136383/14A RU2005136383A (ru) | 2003-04-24 | 2004-04-17 | Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20050014770A1 (enExample) |
| EP (2) | EP2062580A1 (enExample) |
| JP (1) | JP2006524203A (enExample) |
| KR (1) | KR20060007034A (enExample) |
| CN (1) | CN1812792A (enExample) |
| AU (1) | AU2004231306A1 (enExample) |
| BR (1) | BRPI0409796A (enExample) |
| CA (1) | CA2523157A1 (enExample) |
| MX (1) | MXPA05011432A (enExample) |
| RU (1) | RU2005136383A (enExample) |
| WO (1) | WO2004093881A2 (enExample) |
| ZA (1) | ZA200508016B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| RU2530645C2 (ru) * | 2008-11-11 | 2014-10-10 | Берингер Ингельхайм Интернациональ Гмбх | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| BRPI0511054A (pt) | 2004-05-13 | 2007-11-27 | Boehringer Ingelheim Int | uso de dipiridamola para o tratamento de resistência a inibidores plaquetários |
| CA2587026A1 (en) * | 2004-10-25 | 2006-05-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| DE102005028168B3 (de) * | 2005-06-17 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung |
| CA2657270A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New paediatric indications for direct thrombin inhibitors |
| EP2043632A2 (en) * | 2006-07-17 | 2009-04-08 | Boehringer Ingelheim International GmbH | New indications for direct thrombin inhibitors |
| BRPI0715492A2 (pt) * | 2006-07-17 | 2013-03-19 | Boehringer Ingelheim Int | uso de inibidores diretos de trombina |
| WO2009080301A1 (en) * | 2007-12-21 | 2009-07-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke |
| WO2010020601A1 (en) * | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
| US20130131088A1 (en) * | 2010-01-13 | 2013-05-23 | University Health Network | Treating cancer with statins and compounds having dipyridamole activity |
| KR20180074707A (ko) * | 2015-10-15 | 2018-07-03 | 모세 로고스니츠키 | 저 용량 경구 디피리다몰 조성물 및 이의 용도 |
| WO2019241793A1 (en) * | 2018-06-15 | 2019-12-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of detection of mechanically-activated platelet activation and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| GB1051218A (enExample) | 1963-03-09 | |||
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3237575A1 (de) | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| DE3627423A1 (de) | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| DE4035961A1 (de) | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| EP1093814A1 (en) | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
| WO2002034248A2 (en) | 2000-10-20 | 2002-05-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION |
| WO2002060894A2 (en) * | 2001-01-30 | 2002-08-08 | Bristol-Myers Squibb Company | Sulfonamide lactam inhibitors of factor xa |
| EP1250921A1 (en) | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
| EP1308179A1 (en) * | 2001-10-30 | 2003-05-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Improved endoprosthetic device |
| US20030180282A1 (en) * | 2002-03-25 | 2003-09-25 | Victor Serebruany | Method of treatment of thrombotic events |
| WO2004016267A1 (en) * | 2002-08-14 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors |
| WO2004069254A2 (en) * | 2003-02-07 | 2004-08-19 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
-
2004
- 2004-04-17 BR BRPI0409796-3A patent/BRPI0409796A/pt not_active IP Right Cessation
- 2004-04-17 CN CNA200480017862XA patent/CN1812792A/zh active Pending
- 2004-04-17 MX MXPA05011432A patent/MXPA05011432A/es not_active Application Discontinuation
- 2004-04-17 EP EP09152218A patent/EP2062580A1/en not_active Withdrawn
- 2004-04-17 WO PCT/EP2004/004097 patent/WO2004093881A2/en not_active Ceased
- 2004-04-17 EP EP04728114A patent/EP1622621A2/en not_active Withdrawn
- 2004-04-17 RU RU2005136383/14A patent/RU2005136383A/ru not_active Application Discontinuation
- 2004-04-17 CA CA002523157A patent/CA2523157A1/en not_active Abandoned
- 2004-04-17 KR KR1020057020187A patent/KR20060007034A/ko not_active Withdrawn
- 2004-04-17 JP JP2006505175A patent/JP2006524203A/ja active Pending
- 2004-04-17 AU AU2004231306A patent/AU2004231306A1/en not_active Abandoned
- 2004-04-22 US US10/830,294 patent/US20050014770A1/en not_active Abandoned
-
2005
- 2005-10-04 ZA ZA200508016A patent/ZA200508016B/en unknown
-
2006
- 2006-09-01 US US11/469,503 patent/US20070105753A1/en not_active Abandoned
-
2009
- 2009-04-03 US US12/418,001 patent/US20090192123A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| RU2530645C2 (ru) * | 2008-11-11 | 2014-10-10 | Берингер Ингельхайм Интернациональ Гмбх | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060007034A (ko) | 2006-01-23 |
| MXPA05011432A (es) | 2006-03-21 |
| CA2523157A1 (en) | 2004-11-04 |
| BRPI0409796A (pt) | 2006-05-30 |
| US20070105753A1 (en) | 2007-05-10 |
| EP1622621A2 (en) | 2006-02-08 |
| AU2004231306A1 (en) | 2004-11-04 |
| US20050014770A1 (en) | 2005-01-20 |
| EP2062580A1 (en) | 2009-05-27 |
| WO2004093881A2 (en) | 2004-11-04 |
| CN1812792A (zh) | 2006-08-02 |
| US20090192123A1 (en) | 2009-07-30 |
| ZA200508016B (en) | 2007-03-28 |
| WO2004093881A3 (en) | 2005-06-16 |
| JP2006524203A (ja) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005136383A (ru) | Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов | |
| CA2241466C (en) | Pharmaceutical composition containing angiotensin ii antagonist | |
| AU2013334874B2 (en) | Combination therapies for the treatment of Alzheimer's disease and related disorders | |
| US11389435B2 (en) | Compositions and methods for treating epilepsy | |
| TW201219372A (en) | Compositions and methods of treating pulmonary hypertension | |
| US20090247582A1 (en) | Methods of treating atherosclerosis | |
| US20230115611A1 (en) | Treatment of pain and vasoconstriction | |
| WO2005117872A2 (en) | Dual acting snri-nmda antagonists for the treatment of genitourinary disorders | |
| JP2006524203A5 (enExample) | ||
| JP6437444B2 (ja) | 医薬的組合せ | |
| US8618148B2 (en) | Use of telmisartan for the prevention and treatment of vascular headache | |
| JP2006096665A (ja) | 脊柱管狭窄症治療剤 | |
| FI4333840T3 (fi) | Jak1-reitin estäjiä kyhmykutinan hoitoon | |
| KR20060123183A (ko) | 탈리도미드를 포함하는 섬유근육통 치료용 조성물 및 그방법 | |
| WO2010006103A1 (en) | Method for enhancing cognition or inhibiting cognitive decline | |
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| RU2007115092A (ru) | Аминоспиртовые производные | |
| JP2006527244A (ja) | アルツハイマー病及び関連状態の治療 | |
| Vet—QB01AA04 | 1370 Cardiovascular Drugs | |
| WO2006115302A1 (ja) | 神経因性疼痛治療剤 | |
| WO1999007403A1 (fr) | Medicaments nootropes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081205 |